AU2007263278A1 - Combinations comprising staurosprorines - Google Patents

Combinations comprising staurosprorines Download PDF

Info

Publication number
AU2007263278A1
AU2007263278A1 AU2007263278A AU2007263278A AU2007263278A1 AU 2007263278 A1 AU2007263278 A1 AU 2007263278A1 AU 2007263278 A AU2007263278 A AU 2007263278A AU 2007263278 A AU2007263278 A AU 2007263278A AU 2007263278 A1 AU2007263278 A1 AU 2007263278A1
Authority
AU
Australia
Prior art keywords
mcl
typically
lower alkyl
amino
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007263278A
Other languages
English (en)
Inventor
Peter Valent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007263278A1 publication Critical patent/AU2007263278A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007263278A 2006-06-23 2007-06-22 Combinations comprising staurosprorines Abandoned AU2007263278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612542.1A GB0612542D0 (en) 2006-06-23 2006-06-23 Combinations comprising staurosporines
GB0612542.1 2006-06-23
PCT/EP2007/005517 WO2007147613A2 (en) 2006-06-23 2007-06-22 Combinations comprising staurosprorines

Publications (1)

Publication Number Publication Date
AU2007263278A1 true AU2007263278A1 (en) 2007-12-27

Family

ID=36803826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007263278A Abandoned AU2007263278A1 (en) 2006-06-23 2007-06-22 Combinations comprising staurosprorines

Country Status (12)

Country Link
US (1) US20100184820A1 (enExample)
EP (1) EP2037933A2 (enExample)
JP (1) JP2009541240A (enExample)
KR (1) KR20090033874A (enExample)
CN (1) CN101505760A (enExample)
AU (1) AU2007263278A1 (enExample)
BR (1) BRPI0713730A2 (enExample)
CA (1) CA2655724A1 (enExample)
GB (1) GB0612542D0 (enExample)
MX (1) MX2008016488A (enExample)
RU (1) RU2009101972A (enExample)
WO (1) WO2007147613A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
FI20115640A0 (fi) * 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
ES2627500T3 (es) * 2012-07-13 2017-07-28 Turun Yliopisto Terapia de combinación
CN110526903B (zh) * 2016-06-01 2021-12-10 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106083830B (zh) * 2016-06-01 2019-07-12 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
SG10201607303YA (en) 2016-09-01 2018-04-27 Agency Science Tech & Res Antisense oligonucleotides to induce exon skipping
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN107569491A (zh) * 2017-08-30 2018-01-12 杭州科兴生物化工有限公司 一种星孢菌素类化合物的应用
AU2022291381B2 (en) 2021-06-11 2025-04-24 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN114437109B (zh) * 2022-03-08 2023-09-29 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱卤代衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
EP1441737B1 (en) * 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
EP1653973A1 (en) * 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines

Also Published As

Publication number Publication date
KR20090033874A (ko) 2009-04-06
CN101505760A (zh) 2009-08-12
WO2007147613A2 (en) 2007-12-27
WO2007147613A3 (en) 2008-07-03
BRPI0713730A2 (pt) 2012-10-30
CA2655724A1 (en) 2007-12-27
MX2008016488A (es) 2009-01-22
GB0612542D0 (en) 2006-08-02
RU2009101972A (ru) 2010-07-27
JP2009541240A (ja) 2009-11-26
EP2037933A2 (en) 2009-03-25
US20100184820A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
US20100184820A1 (en) Combinations comprising staurosporines
ES2269793T3 (es) Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
CN113924365A (zh) 用于治疗kras相关疾病或病症的组合物和方法
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
JP2012144572A (ja) スタウロスポリン誘導体の新規医薬的使用
US20130195926A1 (en) Modulation of nitric oxide signaling to normalize tumor vasculature
WO2025054270A1 (en) Compositions and methods for treating cancer
US8748428B2 (en) Use of a PKC inhibitor
WO2007143630A2 (en) Treatment of neurofibromatosis with hsp90 inhibitors
EP1768679B1 (en) Modulation of gsk-3beta and method of treating proliferative disorders
US20220333108A1 (en) Combinations of sirnas with sirnas against sulf2 or gpc3 for use in treating cancer
US10617709B2 (en) miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
US20250082652A1 (en) Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
Popescu et al. Multi-selective RAS (ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
US20240141353A1 (en) Sirnas against kras and raf1
WO2021007512A1 (en) Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (gr) binding agents, and/or hsp90 binding agents for uses in treating cancer
Hansen Functional and Therapeutic Relevance of MTAP Deletion in Glioblastoma
AU2008201870A1 (en) New pharmaceutical uses of Staurosporine derivatives
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament
AU2008202050A1 (en) Combinations comprising staurosporines

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted